H.C. Wainwright Maintains Buy rating on BioLife (BLFS) Stock

On May 27, H.C. Wainwright reaffirmed its Buy rating on BioLife Solutions, Inc. (NASDAQ:BLFS) while keeping the price target the same at $30. The bullish sentiment comes after the firm adjusted its financial model for the company.

The company released its fiscal first quarter results for 2025. It delivered a revenue of $23.9 million, up 30% year-over-year. Its Cell Processing platform was a major contributor and added $21.6 million in revenue up 33% year-over-year.

H.C. Wainwright noted that they adjusted their financial model for BioLife Solutions, Inc. (NASDAQ:BLFS), excluding the impact of discontinued operations in their projections. Despite these exclusions, the firm’s projections for the full year remain strong at $97.5 million. Management of the company anticipates full-year revenue along the same lines as it reaffirmed its revenue guidance at $95.5 million to $99.0 million, reflecting 16% to 20% year-over-year growth.

BioLife Solutions, Inc. (NASDAQ:BLFS) is a biotech company that provides specialized cell processing tools and media for the cell and gene therapy market.

While we acknowledge the potential of BLFS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BLFS and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 11 Most Promising New Technology Stocks According to Analysts and 12 Best Growth Stocks to Buy and Hold for the Long Term.

Disclosure: None.